Cancer Society to Issue New Lung Cancer Treatment GL in December; Positioning of Anti-PD-1 Antibodies Will Be Focus of Interest

The Japan Lung Cancer Society (JLCS) is in the process of finalizing its 2016 guidelines for the treatment of lung cancer. How the guidelines position the anti-PD-1 antibodies Opdivo (nivolumab; Ono Pharmaceutical) and Keytruda (pembrolizumab; MSD), which have shown contrasting...read more